期刊文献+

源于Ⅳ型胶原α3、α6链的肿瘤新生血管生成抑制剂 被引量:2

Tumor Angiogenesis Inhibitors Derived from Type Ⅳ Collagen α3,α6 Chains
原文传递
导出
摘要 肿瘤抑素(Tumstatin)和Hexastatin是分别源于Ⅳ型胶原α3、α6链的肿瘤新生血管生成抑制剂.肿瘤的发生、发展和转移都依赖于新生血管的生成.通过抑制肿瘤新生血管的生成,阻断肿瘤细胞赖以生存的氧气及营养供给,肿瘤细胞便会发生凋亡.这是肿瘤治疗的新策略.Tumstatin和Hexastatin是近年来研究比较多的两种肿瘤新生血管生成抑制剂,其中Tumstatin的结构、活性位点、抑制肿瘤新生血管形成机制研究得比较清晰;Hexastatin虽与Tumstatin有许多相似之处,但是还有很多问题需要进一步研究解决.该文就这两种肿瘤新生血管生成抑制剂等的最新研究进展做一综述. Tumstatin and Hexastatin are two tumor angiogenesis inhibitors derived from type Ⅳ collagen α3,α6 chains,respectively.The emergence,progress and metastasis of tumors rely on the generation of new blood vessel.If tumor cells are cut off the supply of oxygen and nutrition through inhibiting new angiogenesis,they will lead to apoptosis.This is the new strategy of tumor therapy in recent years.Tumstatin and Hexastatin are the hot research points among the tumor angiogenesis inhibitors.Meanwhile,the study of Tumstatin goes further and clearer,such as its structure,active site,and mechanism of inhibiting tumors angiogenesis.Hexastatin is a new finding tumor angiogenesis inhibitor.Although Hexastatin has many common characteristics with Tumstatin,a number of problems remain to be studied and solved.In this paper,the new research progress of Tumstatin and Hexastatin will be reviewed.
出处 《中国生物化学与分子生物学报》 CAS CSCD 北大核心 2011年第10期901-906,共6页 Chinese Journal of Biochemistry and Molecular Biology
基金 中国医学科学院放射医学研究所发展基金(No.SF1104,No.ST1113)~~
关键词 肿瘤抑素 Hexastatin 肿瘤新生血管生成抑制剂 Tumstatin Hexastatin tumor angiogenesis inhibitors
  • 相关文献

参考文献1

二级参考文献1

  • 1www. regione.emilia-romagna.it

同被引文献25

  • 1Tanjore H, Kalluri R. The role of type IV collagen and basement membranes in cancer progression and metastasis. Am J Pathol,2006; 168(3) :715-717.
  • 2Xie X, Liu X, Zhang Q, et al. Overexpression of collagen VI α3 in gastric cancer. Oneol Lett,2014 ;7 (5) : 1537-1543.
  • 3Dragutinovic V, Izrael-Zivkovic L, Radovanovic N. Relation of matrix metalloproteinase-9 to different stages of tumors in the serum of gastric cancer. Dig Dis Sci,2009 ;54 (6) :1203-1207.
  • 4Kinoshita J, Fushida S, Harada S, et al. Type Ⅳ collagen levels are elevated in the serum of patients with peritoneal dissemination of gastric cancer. Oncol Lett, 2010 ; 1 (6) :989--994.
  • 5Ando H, Aihara R, Ohno T, et al. Prognostic significance of the expression of MUC1 and collagen type Ⅳ in advanced gastric carci- noma. British Journal of Surgery ,2009 ;96 (8) : 901-909.
  • 6Boulytcheva I V, Kushlinskii N E, Soloviev Y N, et al. Expression of molecular markers in low-grade chondrosarcomas and cartilaginous tumors with uncertain differentiation. Klin Lab Diagn, 2013;(10) : 61-63, 25-30.
  • 7Ohlund D, Lundin C, Ardnor B, et al. Type Ⅳ collagen is a tumour stroma-derived biomarker for pancreas cancer. Br J Cancer, 2009 ; 101 ( 1 ) :91--97.
  • 8吴畏,何剪太,阮景德,王荣兵,张阳德.MMP-2、MMP-9与Ⅳ型胶原在大肠癌中的表达及其相关性研究[J].细胞与分子免疫学杂志,2008,24(9):908-909. 被引量:13
  • 9徐兆发,王雨,王家骏,喻道军,贺安宁,徐斌.亚硒酸钠对镉和汞肝肾氧化损伤影响的实验研究[J].微量元素与健康研究,2008,25(5):1-4. 被引量:3
  • 10李永生,余昌俊,李勇,张雨,张君.VEGFR-3、LYVE-1与胃癌微淋巴管密度及转移相关性研究[J].安徽医科大学学报,2009,44(5):543-546. 被引量:5

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部